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Cystatin F isa cysteineprotease inhibitor that is selectively
expressed in immune cells and unlike other cystatin family
members is targeted to a significant extent to intracellular
compartments. Initially made as an inactive glycosylated
disulfide-linked dimer, cystatin F is converted to an active
monomer by proteolytic cleavage following transport to
the endosomal/lysosomal system. This active form of
cystatin F targets cathepsin C/DPPI and probably other
cathepsins in immune cells. We show that efficient target-
ingofcystatinFtotheendocyticpathwayisdependentnot
on its unique dimeric conformation but rather on its
oligosaccharide chains. We demonstrate the unusual addi-
tion of N-linked sugars to an Asn-X-Cys motif in cystatin F
and provide evidence that the mannose 6-phosphate
sorting machinery is used to divert cystatin F from the
secretory pathway and to mediate its uptake from extra-
cellular pools. These studies identify a function for the
oligosaccharidesoncystatinFand raisethe possibilitythat
cystatin F might regulate proteases in trans by secretion in
an inactiveform byonecellandsubsequentinternalization
and activation by another cell.
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The cystatins are a family of naturally occurring cysteine
protease inhibitors comprising at least 11 members (1,2).
Some are expressed in the cytosol, but the majority are
made with signal sequences and enter the secretory
pathway. Cystatins have been found in many different
body fluids indicating that they have a role in protease
regulation in the extracellular milieu. It is thought that
cystatins are secreted into the extracellular space to inhibit
proteases that may be inadvertently released from cells.
However, it is not clear if this is their only or even their
major function. Nonetheless, their importance is indicated
by the severe phenotypes observed in the absence of
some family members. For example, mice lacking cystatin
E/M exhibit fatal abnormalities in development of the
epidermis (3).
The cystatins are structurally well conserved and comprise
a single a-helix associated with a 5-stranded b-sheet whose
loops combine with residues from the N-terminus to form
an ‘edge’ that engages the protease active site (4). Two
cystatin/protease structures have been solved revealing in
detail how this part of the ‘cystatin fold’ engages a cysteine
protease (5,6). The primary targets of the cystatins are the
papain-related C1 family of cysteine proteases that include
enzymes such as cathepsins B, L and S. Some cystatins
also inhibit the unrelated cysteine protease, asparagine
endopeptidase, but through a distinct structural domain (7).
Cystatin F is an unusual member of the family in several
respects. First, it is primarily expressed by immune cells
(8,9)whereitisoften upregulated whenthese cellsundergo
differentiation or activation from quiescent precursors.
Second,unlikeallotherfamilymembers,cystatinFisinitially
made as a disulfide-linked dimer (10). Moreover, this dimer
is inactive as a protease inhibitor (11) because of mutual
steric hindrance by one subunit of the other subunit’s ability
to bind protease (12). This crucial finding strongly implies
that the domain of action of cystatin F is intracellular
because the secreted extracellular form is inactive. Consist-
ent with this, a greater proportion of cystatin F is retained
within cells compared with cystatin C (9,13). Third, unlike all
other cystatins except cystatin E/M and in some instances
rodent cystatin C (14,15), cystatin F is glycosylated carrying
one (mouse) or two (human) N-linked oligosaccharides.
Finally, the amino acids present in the protease-binding
loops and N-terminal region of cystatin F are not homolo-
gous with those of other family members, indicating that
cystatin F might bind distinct protease targets (8,9).
We recently strengthened the notion that cystatin F regu-
lates intracellular rather than extracellular protease activity
by showing that a principle target is cathepsin C (16). This
enzyme is an important aminopeptidase that activates
a variety of serine protease zymogens in the secretory
granules of cytotoxic T lymphocytes (CTL), natural killer
cells, mast cells and neutrophils (17–19). Although disrup-
tion of the cystatin F dimer is sufficient to generate an
inhibitor of endopeptidases such as cathepsin L, a proteo-
lytic cleavage event was required to convert inactive
cystatin F into an active cathepsin C inhibitor. This cleavage
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dimeric cystatin F into a monomeric form (16). This surpris-
ing finding also points to an intracellular domain of action.
How cystatin F is localized within the endocytic pathway
when other family members are secreted has not been
investigated. Several possibilities might account for its
intracellular targeting. For example, the unique dimeric
conformation of cystatin F may be important perhaps
creating a recognition feature lacking in monomeric cys-
tatins. Alternatively or additionally, one or both of the two
canonical N-linked carbohydrate motifs may provide the
necessary sorting signals. Third, because cystatin F is only
35% homologous to other family members, there may be
other less obvious targeting motifs involved in its intracel-
lular trafficking.
Here, we investigate how cystatin F is retained within cells
by analysis of cystatin F mutants that either cannot
dimerize or lack specific oligosaccharide chains. We show
that cystatin F molecules that cannot dimerize are still
efficiently targeted to the endosomal system. Moreover,
a mutant of cystatin F lacking both canonical N-linked
carbohydrate chains was also activated normally within the
endocytic pathway. However, this ‘non-glycosylated’ var-
iant of cystatin F retained sensitivity to treatment with
N-glycosidase F (PNGase) because of carbohydrate addition
on a cryptic noncanonical (Asn-X-Cys) N-glycosylation site.
Either this site, or a neighboring canonical site, sufficed to
specify sorting of cystatin F to lysosomal compartments.
We further show that cystatin F made and secreted by one
cell can be internalized and activated within a different cell
through mannose 6-phosphate (M6P)-mediated targeting.
Thus, immune cells expressing cystatin F may regulate
in trans the protease activity of bystander cells.
Results
Cystatin F dimerization is not required for
intracellular targeting
To investigate the trafficking of cystatin F, we generated
various mutant forms and analyzed these initially in the
human kidney epithelial cell line 293T, which does not
express cystatin F. The cells were transfected, and after
48 h, the relative amount of cystatin F in cell lysates (L) and
in the culture medium (M) was assessed. Expression of
wild-type cystatin F leads to significant secretion of the
protein into the culture medium as we and others have
previously reported (10,13,16). Nonetheless, a significant
amount of cystatin F was also retained in 293T cells and
was partially converted to the monomeric form (Figure 1A,
left panel). Cystatin F recovered from the culture medium
was dimeric, whereas cellular cystatin F comprised a mix-
ture of dimeric and monomeric protein (Figure 1A, left
panel). Furthermore, while the dimeric form reacted with
antibodies raised against the N-terminus of cystatin F
the monomeric form did not, indicating intracellular pro-
cessing had occurred as we recently reported (Figure 1A,
center panel) (16). As shown previously, heterogeneous
N-glycosylation accounted for the resolution of distinct
forms of cystatin F on SDS–PAGE (9). This is highlighted by
the formation of a single form following treatment
with PNGase (Figure 1A, right panel).
Cystatin F dimerizes through two disulfide bridges involv-
ing Cys26 on one subunit and Cys63 on the other (12). We
first asked whether intracellular retention of cystatin F was
dependent on dimerization by transfecting 293T cells with
a cysteine to serine double mutant (C26,63S cystatin F).
The expressed protein was monomeric, as expected.
Moreover, a similar proportion was retained within the
cells when compared with wild-type cystatin F (Figure 1A,
left panel), indicating that dimerization is not necessary to
divert cystatin F from the secretory to the endocytic
pathway. Monomeric cystatin F appeared to be glycosy-
lated normally as judged by its mobility and sensitivity to
PNGase (Figure 1A). In addition, a proportion of mono-
meric cystatin F was N-terminally processed as judged by
the reactivity of the fastest migrating form with antibody
raised against whole cystatin F but not with the N-terminal-
specific N1 antibody (Figure 1A, asterisk).
To confirm targeting to the endocytic pathway, transfected
cells were fixed and stained with antibodies against
cystatin F and a marker of the late endosomal/lysosomal
compartment (CD63). As shown in Figure 1B, cystatin F
partially colocalized with CD63 indicating lysosomal local-
ization. Moreover, C26,63S cystatin F was also colocalized
with lysosomal markers.
Although covalent dimer formation was circumvented by
substitution of the two cysteines involved in disulfide bond
formation with serine, noncovalent dimer formation was
still plausible. In other words, dimerization of C26,63S
through noncovalent interaction may account for its lyso-
somal localization and secretion. To address this, wild-type
and C26,63S cystatin F were subject to size exclusion
chromatography on a column calibrated with standard
proteins of known molecular weight and stokes’ radii.
Elution of cystatin F was initially followed by absorption
(280nm) of the eluted fractions and then confirmed by
western blot (Figure 1C). As expected, wild-type cystatin F
eluted as a single species and had a calculated stokes’
radius of 3.19 nm (Figure 1C, top panel). Likewise,
C26,63S cystatin F eluted as a single species but with
a smaller calculated stokes’ radius of 2.35 nm (Figure
1C,D). SDS gel analysis of individual column fractions
confirmed that C26,63S cystatin F was included in the
column to a much greater extent than wild-type protein.
Together, these data indicate that while cystatin F dimeri-
zes, is glycosylated and a proportion is targeted to the
endocytic pathway in 293T cells, dimerization is not
necessary for these post-translational modifications or for
its targeting.
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occur on cystatin F
We next assessed the possibility that glycosylation of
cystatin F was important for targeting the endosomal/lyso-
somal system. In human cystatin F asparagines 62 and 115
carry carbohydrate chains, whereas murine cystatin F carries
a single N-linked sugar at a site homologous to Asn62 in
humans. We generated mutant forms of human cystatin F
where one or both Asn residues were altered to Ser (N62S,
N115S and N62,115S) and transfected these into 293T cells.
Culture medium and cell lysates were then analyzed for the
presence of cystatin F and digested with PNGase to assess
its glycosylation status. Similar to wild-type cystatin F, all
mutant forms of cystatin F migrated as a single band
following treatment with PNGase. Puzzling, however, the
gel mobility of the N62S mutant in the absence of PNGase
digestion was similar to that of wild type (Figure 2A). Even
more surprising is that the double mutant N62,115S, which
we predicted would not be glycosylated, migrated as two
species, one of which retained sensitivity to digestion with
PNGase. Because N62 and N115 are the only Asn residues
found in a conventional Asn-X-Thr/Ser glycosylation consen-
sus sequence, these results pointed to the existence of an
unusual glycosylation site on cystatin F. Glycosylation of Asn
residues in the context an atypical Asn-X-Cys sequence has
previously been observed, for example in the recombinant
epidermal growth factor receptor, the T-cell activation anti-
gen CD69 and a few other proteins (20,21). As shown in
Figure 2B, Asn61 of cystatin F also occurs in this context.
We therefore tested the hypothesis that mutagenesis of
Asn62 might reveal a cryptic noncanonical glycosylation site
at Asn61. Consistent with this possibility, the double mutant
Figure 1: Cystatin F subcellular localization and secretion does not depend on dimer formation. A) SDS–PAGE separated cell
lysates (L) and culture medium (M) under nonreducing conditions from 293T cells transfected with wild-type or C26,63S human cystatin F.
Western blots were probed with an antibody raised against full-length cystatin F (FL Ab) (left and right panels) or an N-terminal peptide
(N-term Ab) (center panel). Right panel shows change in mobility following deglycosylation with PNGase under reducing conditions. Open
and closed arrowheads denote dimeric and monomeric cystatin F, respectively. Asterisk denotes N-terminal processing of the C26,63S
mutant. B) Immunofluorescence microscopy of 293T cells shown in (A) expressing wild-type or C26,63S cystatin F (red) and
counterstained with an antibody to the lysosomal marker CD63 (green). Insets demonstrate areas of colocalization at high magnification.
Bars, 10 mm. C) Western blot analysis following size exclusion chromatography. Nonreducing SDS–PAGE gel analysis of equal sized
aliquots of column fractions obtained following chromatography of wild-type (top panel) or C26,63S (bottom panel) cystatin F. D) The
Stokes’ radius of wild-type (3.19 nm) and C26,63S (2.35 nm) cystatin F were calculated following size exclusion chromatography. Values
were interpolated from the calibration curve obtained by the linear fitting of Stokes’ radius versus ( log Kav)
1/2 for a series of proteins with
known Stokes’ radii, as described. Protein calibration was obtained using ribonuclease A (a), carbonic anhydrase (b), ovalbumin (c) and
conalbumin (d).
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and the triple mutant N61,62,115S was fully resistant to the
action of PNGase (Figure 2C). Thus, the Asn
61-X-Cys
63
sequence in cystatin F can be used by the glycosylation
machinery.
Glycosylation of either Asn61 or Asn62 is required
for cystatin F targeting to endosomes
Analysis of the trafficking of the Asn61 mutant produced
another important result. Whereas the N62,115S mutant
was still targeted to intracellular compartments (data not
shown), the N61,62S mutant and the triple mutant were
largely absent and found mostly in the medium (Figure
2C). Consistent with this, we could not detect colocaliza-
tion of the N61,62S or N61,62,115S mutant with markers
of the lysosomal pathway (Figure 2D). Moreover, in contrast
to cells expressing wild-type and N115S mutants, cathepsin
C activity was not inhibited (Figure S1). Instead, any cystatin
F remaining within these cells colocalized with the markers
of the trans-Golgi network indicative of protein destined for
secretion (Figure 2D). These results indicate that glycosyla-
tion of cystatinF is important for its intracellular targeting and
Figure 2: Mutagenesis of consensus sequences for N-linked glycosylation reveals an atypical glycosylation site. A) Reducing SDS–
PAGEanalysisofmutantsofone(N62SorN115S)orboth(N62,115S)N-linkedglycosylationsequences.RemainingglycosylationofcystatinF
(Cyst. F) is revealed by comparing untreated samples ( ) to PNGase treatment (þ). (B) Human cystatin F amino acid residues 61–63 (NXC)
represent a potential atypical N-linked glycosylation site. (C) Reducing SDS–PAGE comparing glycosylation of double (N61,62S) and triple
(N61,62,115S) Asn mutants in the presence (þ) or absence ( ) of PNGase. Representative cell lysates (Lys) and culture medium (Med) are
shown. (D) Immunofluorescence microscopy following transfection of 293T cells (as in C) with antibodies raised against full-length cystatin F
(red) and markers of lysosomes (CD63) or the trans-Golgi network (TGN46) (green). Insets reveal areas of costaining. Bars, 10 mm.
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In contrast, glycosylation of Asn115 does not appear to be
involved in the intracellular targeting of cystatin F.
Mannose 6-phosphorylation is used to target
cystatin F to endosomes
Many lysosomal hydrolases carry N-linked glycans that
become modified with M6P and use the cation-dependent
or -independent M6P receptors (CD-MPR or CI-MPR, res-
pectively) for targeting the endocytic pathway (22). We
asked whether cystatin F might also utilize the M6P system
to reach endosomes and lysosomes. First, we looked for
evidence that one or more of the oligosaccharides on
cystatin F were phosphorylated. As shown in Figure 3A,
cystatinFbecamelabeledwith[
32P] orthophosphatein293T
cells, and this label was removed by treatment with endo-
b-N-acetylglucosaminindase H (EndoH), suggesting phos-
phorylation occurred on high mannose glycans. In contrast,
[
35S]-labeled cystatin F migrated faster following treatment
with EndoH, but the label was not removed. Next, we
infected mouse fibroblasts, including those lacking the
CI-MPR, with a retrovirus expressing wild-type cystatin F.
Whereas L929 cells, which express wild-type levels of both
MPR, retained a proportion of cystatin F and converted it to
the monomeric form, no intracellular cystatin F could be
detectedinLcellslackingtheCI-MPRs(Figure 3B).Cystatin
F retention and N-terminal processing were restored in
knockout L cells reconstituted with the CI-MPR (Figure 3B).
Cellular acquisition of exogenous cystatin F
The itinerary of the CI-MPR is known to include the cell
surface and many studies have demonstrated its ability to
mediate internalization of extracellular M6P-tagged en-
zymes. Our finding that intracellular targeting of cystatin
F could use the M6P system raised the possibility that
secreted cystatin F might enter cells using the same
system. More generally, the internalization and subse-
quent activation of inactive dimeric cystatin F would in
principle allow proteases to be regulated in trans, that is in
cells not expressing cystatin F.
We first asked whether cystatin F secreted by 293T cells
could be taken up by other cells and if so whether
internalization was dependent on cystatin F glycosylation.
We collected the culture medium from 293T cells trans-
fected with the various N-glycosylation mutants of cystatin
F described above (Figure 4A, left panel) and incubated
these conditioned media with L929 cell monolayers. After
48 h, the recipient cells were tested for internalization and
processing of cystatin F. L929 cells not only acquired wild-
type cystatin F but also converted the inactive dimer to the
monomeric form (Figure 4A, right panel). Although N115S
cystatin F was also taken up by L929 cells, the N61,62S
and N61,62,115S forms of cystatin F were not (Figure 4A).
The internalization of cystatin F glycan mutants N62S or
N62,115S further confirmed the requirement of glycosyl-
ation at one of these important residues. Surprisingly,
monomeric cystatin F (C26,63S) and a mutant mimicking
the N-terminally processed cystatin (DN cystatin F) (16)
failed to be internalized (Figure 4B). As shown in Figure
4C, C26,63S cystatin F, like wild-type cystatin F, still
acquired EndoH-sensitive phosphate residues indicating
that monomeric cystatin F was also modified with M6P
(Figure 4C). These data suggest that in addition to glyco-
sylation of N61 or N62, a dimeric and presumably dually
phosphorylated protein must be present. We confirmed
these results by immunofluorescence microscopy. Wild-
typeandN115ScystatinF,butnotN61,62SorN61,62,115S
cystatin F, were taken up and became colocalized with
CD63 (Figure 4D). Importantly, internalized cystatin F
became active as a protease inhibitor within the recipient
cells because endogenous cathepsin L and cathepsin C
activity was suppressed. In contrast, there was no inhibi-
tion of these proteases in cells incubated with N61,62S or
N61,62,115S cystatin F (Figure 4E).
To establish whether the glycosylation-dependent internali-
zation of cystatin F utilized the M6P system, we repeated
Figure 3: Cellular retention of cystatin F requires the CI-MPR.
A) 293T cells transfected with wild-type cystatin F were radiolabeled
with [
32P] orthophosphate (left panel) or [
35S] methionine/cysteine
(right panel). Labeled cystatin F in postnuclear lysates (Lys) and
culture medium (Med) were immunoprecipitated and either left
untreated ( ) or treated with EndoH (þ) followed by SDS–PAGE
underreducingconditions.B)Retroviruscontainingwild-typehuman
cystatin F was used to infect L929 cells, L cells lacking the CI-MPR
(CI-MPR KO) or the CI-MPR KO reconstituted with the CI-MPR
(KOþCI-MPR). Cystatin F in cell lysates (L) and culture medium (M)
was detected bywesternblot using the FL AbfollowingSDS–PAGE
under nonreducing conditions. Open and closed arrowheads denote
dimeric and monomeric cystatin F, respectively. Actin staining is
used to show equivalent protein loaded.
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concentrationsofM6P.AsshowninFigure 5A,accumulation
of monomeric cystatin F by L929 cells was significantly
blocked in the presence of 0.5 mM M6P and almost com-
pletely by higher concentrations of M6P (Figures 5A,B). This
blockade was specific for M6P as pretreatment with man-
nose or fucose failed to inhibit cystatin F internalization
(Figure S2). However, there was a small fraction of dimeric
cystatin F associated at these concentrations of M6P. We
also tested mouse embryonic fibroblasts (MEF) isolated
from either wild-type or MPR knockout mice. Whereas
monomeric cystatin F accumulated in wild-type MEF and
in knockout MEF reconstituted with the CI-MPR, knockout
MEF themselves accumulated much less monomer
Figure 4: Secreted cystatin F can be internalized in a carbohydrate-dependent manner. A) Equal concentrations of secreted wild-
type andglycosylationmutant cystatinF (Cyst. F)produced by293T cells(left panel) were culturedwith L929 cellsfor48 h. L929cell lysates
wereseparatedbySDS–PAGEundernonreducingconditionswithmembranesimmunoblottingforinternalizedcystatinFusingtheindicated
antibody (center and right panel). B) Equal concentrations of secreted glycosylation mutants (N62S and N62,115S) and mutants rendering
cystatin F monomeric (C26,63S and DN cystatin F) produced by 293T cells (left panel) were cultured with L929 cells as described in (A) and
were stained with the FL Ab (right panel). Cystatin F dimeric species (open triangles) and monomeric species (closed triangles) are shown.
Actinstainingindicates equal protein loading. C) 293T cellstransfected with C26,63S cystatinF were radiolabeled with [
32P] orthophosphate
(left panel) or [
35S] methionine/cysteine (right panel). Labeled cystatin F in postnuclear lysates (Lys) and in the culture medium (Med) were
immunoprecipitated using the cystatin F polyclonal antibody and either left untreated ( ) or were treated with EndoH (þ) followed by SDS–
PAGEunder reducingconditions.D)Immunofluorescent labelingofinternalized cystatinF (red)inL929cellsandthelysosomalmarkerCD63
(green). Insets demonstrate areas of colocalization at high magnification. Bars, 10 mm. (E) Cathepsin activities in 293T cells (cathepsin C;
light gray) and L929 cells (cathepsin L; dark gray) exposed to cystatin F-conditioned medium. Data represent the mean rate of more than
three independent experiments. Error bars indicate the SEM. Significant differences of *p < 0.02 and **p < 0.005.
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cystatin F continued to associate with these cells as did
some faster migrating cystatin F. However, this cystatin F
did not co-migrate with the monomer taken up by wild-type
cells, although it appeared to be N-terminally processed
(Figure 5C, center and right panel). To examine whether the
residual cystatin F association with cells devoid of MPR was
carbohydrate dependent, we exposed wild-type and knock-
out MEFs to unglycosylated cystatin F. As shown in Figure
5D, internalization of N61,62,115S cystatin F was com-
pletely blocked irrespective of the presence or absence of
the MPR. These results show that internalization and
activation of cystatin F is at least partially dependent on
the MPR system and is completely dependent on glycosyl-
ation of cystatin F.
Cystatin F production and internalization by
immune cells
Finally, we asked whether secretion of cystatin F by one cell
and internalization by another could be demonstrated in
primary immune cells. We found that significant amounts of
dimeric cystatin F were secreted from primary CD8
þ T
lymphocytes and bone marrow-derived dendritic cells
(BMDC). As expected, the cell lysates also contained cystatin
F, much of which was converted to the active monomeric
form (Figure 6A). We recently generated cystatin F-deficient
mice that are currently being analyzed. These mice were
used to generate a population of cystatin F-negative CD8
þ T
cells by in vitro expansion. We incubated these cells with an
equal number of wild-type CD8
þ T cells and asked whether
cystatin F was acquired by the null cells. We used the CD45
marker and fluorescence-activated cell sorter (FACS) analysis
to distinguish wild type (CD45.1
þ) from cystatin F null
(CD45.2
þ) cells (Figure 6B, top panel). As shown in Figure 6
C, a small proportion of CD45.2
þ cells became positive for
cystatin F during the course of the experiment demonstrating
that the protease inhibitor had been taken up by the null cells
(Figure 6C, bottom panel). This important result indicates
that one cell may influence the protease activity of another
through the agency of cystatin F.
Figure 5: Internalization and activation of cystatin F is dependent on the CI-MPR. A) L929 cells cultured in media conditioned by
cystatin F-transfected 293T cells (represented in the left panel) in the absence or presence of decreasing concentration of free M6P (5.0–
0.05 mM final). B) [
125I]-labeled recombinant human cystatin F was cultured with L929 cells in the presence or absence of free M6P for
30 min at 378C. The percent of cystatin F internalized was measured by comparing surface bound [
125I]-labeled cystatin F at 0 min with
internalized cystatin F at 30 min as described in the Materials and Methods. C) Cystatin F-containing medium (left panel) was cultured with
wild-type MEF, MPR knockout MEF (MPR KO) or in fibroblasts reconstituted with only the CI-MPR. Left and center panels display gels
probed with the FL Ab. Right panel shows MEF lysates probed with the N-term Ab. D) Unglycosylated cystatin F (N61,62,115S)-containing
medium (left panel) was cultured with either wild-type MEFs, MPR KO MEFs or in reconstituted MEFs (right panel). Western blots were
probed with the FL Ab. All gels were run under nonreducing conditions. Open and closed arrowheads denote dimeric and monomeric
cystatin F, respectively. Actin staining is used to show equivalent total protein loaded.
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was active in recipient primary T cells. However, it was not
feasible to analyze proteolytic activity in the relatively small
number of cells that had acquired cystatin F because their
identification necessitated fixation and permeabilization
before FACS analysis. To establish that protease activity
in primary T cells can be attenuated by exogenous cystatin
F, we cultured cystatin F knockout splenocytes with recom-
binant cystatin F for 48 h and followed its internalization
by intracellular FACS analysis and microscopy. A parallel
culture was then lysed and cathepsin C protease activity
was analyzed in the cystatin F-treated and untreated
populations. Internalization of cystatin F under these con-
ditions resulted in its proper localization (Figure S4A,B).
Moreover, although not all T cells acquired cystatin F,
cathepsin C activityin the bulk populationwas substantially
reduced in the cystatin F-exposed cells (Figure S4C),
demonstrating that internalized cystatin F was active. This
result further indicates that cystatin F secreted by one cell
may attenuate protease activity in another cell.
Discussion
The mechanism of action of cystatin F appears to constitute
a new paradigm for regulation of protease activity in the
endocytic pathway. Following biosynthesis, its activity is
quenched because of its unique dimeric conformation (12).
Some of this form is secreted from cells but a substantial
proportion is targeted to the endocytic pathway where pro-
teolysis converts the dimer to active monomers. In immune
cells, this form inhibits cathepsin C/DPPI and probably other
cathepsins (16). The existence of a protease-activated pro-
tease inhibitor clearly suggests a novel mechanism for feed-
backattenuationofproteaseactivityintheendocyticpathway.
How cystatin F is targeted to the endocytic pathway is an
important and unresolved issue that we investigated here.
Most cystatins made with signal sequences (type II
cystatins) are secreted from cells, suggesting that their
primary function is to inactivate potentially dangerous
proteases that have been secreted or lost from cells into
the extracellular space thereby protecting from inflamma-
tory reactions associated with aberrant release of these
proteases (23–25). While cathepsins have been shown to
be secreted from cells and have been shown to exhibit
protease activity at neutral pH (26–28), their inhibition by
secreted cystatins has not been demonstrated. Cystatin F
has also been shown to be secreted (9); however, recent
data suggest that the primary targets for cystatin F are
intracellular. First, the relative concentration of cystatin F
within cells compared with that which is secreted is much
higher than for the other type II family members (13).
Second, our recent findings suggest that one of the true
physiological targets of cystatin F is cathepsin C, which is
found in the endocytic compartment (16). Inhibition of this
aminopeptidase requires that cystatin F undergoes an
N-terminal proteolytic processing step occurring in intracel-
lularcompartmentswhereproteaseactivityanditscathepsin
targetsarelikelytoreside(16).Third,cystatinFissecretedas
an inactive disulfide-linked dimer, and to date, the active
monomeric form has only been observed intracellularly
(11,16). Together, these data suggest that cystatin F inhib-
itory activity is restricted to the endocytic compartment.
The mechanism by which cystatin F is retained within cells
and matured in the endocytic compartment is addressed
here. We demonstrate that dimerization is not necessary
for intracellular cystatin F to be directed to the lysosomal
pathway but rather a carbohydrate-dependent sorting
mechanism operates. Our findings provide an explanation
for why cystatin F is glycosylated when almost all other
family members are not. Cystatin M/E is also glycosylated
and is found in the lamellar granules of the cells of the
stratum granulosum of the skin as well as in extracellular
locations(29). WhetherlocalizationofcystatinM/E inthese
granules also depends on its glycosylation is not known.
To our knowledge, cystatin F is the first lysosomal pro-
tease inhibitor shown to be M6P modified. This appears to
Figure 6: Internalization and activation of cystatin F in pri-
mary cells. A) Lysates (L) and medium (M) from cultured primary
murine CD8
þ T lymphocytes (CTL) and dendritic cells (BMDC)
isolated from spleen and bone marrow, respectively. B) Lysates
from activated CD45.1
þ (wild type) and CD45.2
þ (knockout) CTLs
were separated by nonreducing SDS–PAGE and immunoblotted
for cystatin F (Cyst. F). Arrowheads denote dimeric (open) and
monomeric (closed) cystatin F. Actin staining is used to confirm
equivalent protein loading. C) CD45.1
þ wild-type splenocytes
were cocultured with CD45.2
þ cystatin F knockout splenocytes
for 48 h. Internalization of cystatin F into CD45.2
þ cells was
determined by intracellular immunostaining (after coculture).
Numbers represent percentage of CD45.2
þ cells staining for
cystatin F before and after coculture. FACS data are representa-
tive of at least three independent experiments.
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Colbert et al.be integral for proper targeting to the lysosomal compart-
ment as judged by the failure of cells lacking MPRs to
retain cystatin F. An earlier report identified cystatin F as
one of several secreted proteins recovered from an MPR
column, although it was not clear if the association was
direct or indirect, for example through a binding partner
modified with M6P (30). Our data indicate that binding to
the MPR column was most likely direct. Studies in cells
derived from mice lacking both 46 and 300 kD MPRs
demonstrate that some cell types have additional mecha-
nisms for intracellular targeting of lysosomal hydrolases
(31,32). It is possible that cystatin F also utilizes such
mechanisms depending on cell type.
Human cystatin F carries two N-linked oligosaccharides at
Asn62 and 115, whereas murine cystatin F lacks the
second sugar. Consistent with conservation of glycosyla-
tion at position 62 in mammalian cystatins (Figure S3), we
show that this sugar carries targeting information,
whereas the Asn115-linked sugar does not. Surprisingly,
elimination of both Asn62 and 115 revealed a cryptic N-
linked glycosylation site at Asn61, which utilized the non-
canonical motif Asn-X-Cys-Ser/Thr and which sufficed to
target cystatin F correctly in the absence of the canonical
Asn62-linked sugar. The Asn61 residue is conserved in all
cystatin F sequences deposited thus far (Figure S3). Other
proteins have been shown to direct glycans at sites
containing cysteine rather than serine or threonine at the
third position. Like cystatin F, several include atypical
sequences where a serine or threonine residue at the
fourth position in conjunction with a cysteine at the third
position (NXCS/T) is present. These include the immune
regulator CD69 and human protein C (20,21,33). Whether
Asn61 and Asn62 are both modified in wild-type cystatin F
is not yet clear. Because the cysteine residue (C63) in the
Asn-X-Cys motif is involved in the dimerizing disulfide
bond, presumably recognition of the motif and addition
of core oligosaccharide to Asn61 must occur before
dimerization and loss of the free thiol. However, this has
not been formally demonstrated.
High concentrations of reducing agents are required to
reduce the cystatin F dimer making a proteolytic mecha-
nism for monomerization more likely and linking cystatin F
activation to endosomal proteolytic activity rather than
reducing potential (11,16). Based on the crystal structure
of cystatin F, we suggested earlier that an additional
function for the oligosaccharide at Asn62 (and perhaps
Asn61) may be to shield the disulfide bonds linking the
monomers (12). However, as cystatin F lacking oligosac-
charides at Asn61 and Asn62 is secreted, this remains
a hypothesis because we are unable to assess whether
this dimer is more sensitive to reduction in vivo.
Sequestration of cystatin F from the secretory pathway
by an M6P/MPR mechanism raised the possibility that
secreted dimeric cystatin F might be taken up into cells
using the same system, as first described by Neufeld and
colleagues for lysosomal enzymes (34). We found that
different cell lines and primary cells were able to internalize
inactive dimeric cystatin F and convert it to its active
monomeric form. Moreover, this internalization and con-
version was inhibited by free M6P sugar and was reduced
in cells lacking MPRs. Importantly, we could demonstrate
suppression of protease activity in the recipient cell as
well as exchange of cystatin F between immune cells.
We noticed that secreted monomeric cystatin F was not
internalized although, like wild-type cystatin F, it was
phosphorylated on high mannose glycans and was tar-
geted to lysosomes during biosynthesis. Conceivably, the
increased avidity provided by two M6P modified sugars in
the dimer for the CI-MPR accounts for this observation
(35). It is also important to note that soluble monomeric
M6P could not completely suppress cystatin F internali-
zation into L929 cells, and consistent with this, some
internalization still occurred in cells lacking MPRs. How-
ever, additional mechanisms for targeting secreted lyso-
somal enzymes exist such as the multiligand receptor
megalin (36,37); carbohydrate-specific-binding lectins such
as the galactose-, fucose- and mannose-binding receptors
(38–40) and glycosaminoglycan (GAG)-binding receptors
such as CD44 and the hyaluronic acid receptors (41,42),
among others. It is possible that one or more of these
mechanisms contribute to cystatin F targeting and endo-
cytic uptake. Indeed, a recent report shows that human
cystatin C, which is monomeric and unglycosylated (43),
can be taken up by cells via an unknown mechanism (44).
However, the role of carbohydrates associated with cys-
tatin F is highlighted by the fact that unglycosylated
cystatin F was not internalized by target cells. Further-
more, in the absence of M6P targeting, most endocytosed
cell-associated cystatin F remained in the dimeric form,
suggesting that efficient transport to the compartment
where proteolytic conversion occurred required the M6P/
MPR system.
These results raise the possibility that immune cells
secreting cystatin F may be able to regulate protease
activity in neighboring cells that either do not express
cystatin F or express insufficient levels. Cystatin F ex-
pressing primary cell populations such as CD8
þ T cells
often show heterogeneous levels of expression. There-
fore, secretion and internalization of cystatin F in the
closely confined in vivo milieu may even out these differ-
ences in expression. Cystatin F may be transferred effi-
ciently from one cell to another not only because of its
M6P tag but also because, unlike other cystatins found in
the external milieu, it is unable to bind protease targets and
therefore will not be sequestered by extracellular cysteine
proteases. Several precedents exist for in vivo acquisition
of lysosomal enzymes by one cell type following secretion
by another. For example, cathepsin L-deficient thymocytes
acquired this enzyme from surrounding epithelial cells
rescuing a defect in antigen presentation and development
of natural killer T cells (45). In another example, procathep-
sin B was taken up in vivo from the glomerular filtrate into
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B deficiency (36). Although we have not yet demonstrated
transfer of cystatin F between cells in vivo, our results
clearly indicate that this may take place. Conceivably, given
that cathepsin C is one of the targets of cystatin F, this may
be a way of attenuating granule protease-driven inflamma-
tory reactions.
In summary, our study sheds light on the unusual features
of the cystatin F molecule. Glycosylation and more speci-
fically M6P modification serve to target it to the endocytic
pathway during biosynthesis, and for a proportion of
molecules, by endocytosis from the external medium
(Figure 7). In the event when Asn62 is not modified,
a ‘backup’ noncanonical N-linked M6P-modified sugar
can be added to Asn61. Although the dimeric form is not
crucial for intracellular targeting, it appears to be necessary
for endocytic uptake. Moreover, dimerization ensures the
latency of the inhibitor, which only becomes active follow-
ing activation by proteases. The possibility that cystatin F is




Cell culture media were purchased from Gibco unless otherwise indicated.
H-Gly-Phe-AMC and Z-Phe-Arg-AMC were purchased from Bachem.
PNGase and EndoH were purchased from Roche. Rabbit polyclonal anti-
bodies directed against full-length human cystatin F (FL Ab) or against an
N-terminal peptide (aa20-35; N-term Ab) have been described previously
(16). Mouse anti-CD63 was purchased from Abcam. Sheep anti-TGN46
antibody was a kind gift from Dr S. Ponnambalam (University of Leeds, UK).
Mouse monoclonal actin antibody was purchased from Sigma-Aldrich. All
secondary antibodies used for western analysis were purchased from
Jackson Laboratories. Antigen-presenting cell (APC)-conjugated CD45.2,
CD8 and CD11c were purchased from eBioscience. Quik Change Site-
Directed Mutagenesis kit was purchased from Stratagene. Protein stand-
ards for determination of stokes’ radii were obtained from GE Healthcare.
Cell culture
The cell lines 293T and L929 were cultured in DMEM supplemented with
10% fetal calf serum (FCS), 2 mML - glutamine, 100 U/mL penicillin and
100 mg/mL streptomycin. L cells devoid of the CI-MPR (CI-MPR KO), and
those reconstituted with the CI-MPR (KO þ CI-MPR) were kindly provided
by T. Braulke (University Hospital Hamburg, Germany) and were cultured in
the same medium as L929 cells. Wild-type MEF, MPR knockout fibroblasts
and those reconstituted with the human CI-MPR were generous gifts from
R. Pohlmann (Westfa ¨lische Wilhelms-Universita ¨tM u ¨nster, Germany) and
B. Hoflack (Biotechnological Center, Technical University of Dresden,
Germany) and were cultured as described (46). Dendritic cells and CD8
þ
T lymphocytes were cultured from the bone marrow and spleen, respec-
tively, of C57BL/6 mice as described previously (16,47). C57Bl6-Ly5.1
þ
(CD45.1
þ) mice were a kind gift from P. Crocker (University of Dundee, UK).
Cystatin F knockout mice were generated under contract by Artemis
Pharmaceuticals GmbH and will be fully described elsewhere.
Site-directed mutagenesis and deglycosylation
of cystatin F
Mutagenesis was performed using plasmids encoding full-length human
cystatin F cDNA in a pcDNA-DHFR expression vector as described pre-
viously (16). Cysteine mutants were constructed at amino acids C26 and
C63 by exchanging the Cys to Ser as described previously (16). Glycosyl-
ation mutants were constructed at amino acids N61, N62, N115S or







derline denotes substituted residues. All mutagenesis was performed using
the Quik Change Site-Directed Mutagenesis kit. Glycosylation of cystatin F
was assessed by treating cell lysates, conditioned medium or immunopreci-
pitated cystatin F with PNGase to remove the entire glycan or EndoH to
selectively remove high mannose forms of the glycans according to manu-
facturer’s guidelines.
Transfection, transduction and protease assays
293T cells were transfected with plasmids containing either full-length
(wild type) or mutant cystatin F following manufacturer’s instructions
(Lipofectamine 2000; Invitrogen). Human cystatin F was transduced into
murine L929 and L cells using the retroviral vector pBMN-I-GFP (Addgene,





























Figure 7: Proposed model describing the requirement of cystatin F glycosylation for intracellular targeting and internalization.
Cystatin F is synthesized as an inactive glycosylated disulfide-linked dimer. M6P modified glycans direct cystatin F to lysosomes where
N-terminal proteolysis induces its activation (processed cystatin F). A proportion of inactive dimeric cystatin F is secreted where it binds
membrane receptors, such as the CI-MPR, on adjacent cells. Internalization of cystatin F leads to a M6P-dependent lysosomal localization
where N-terminal processing results in its activation.
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Colbert et al.and transfected cells were left in culture for 48 h after which cystatin
F-enriched medium and cells were separated by centrifugation. Cells were
washed and lysed in buffer containing 100 mM citrate, pH 5.4, 150 mM
NaCl, 2 mM MgCl2 and 1% Triton-X-100. Culture media and cell lysates
were analyzed for cystatin F expression by western blot using antibodies
directed against the whole protein (FL Ab) unless otherwise noted. Protein
concentrations in cell lysates were quantified by Bio-Rad Protein Assay
(Bio-Rad). Equivalent concentrations of cystatin F in culture medium were
determined by western blot and normalized before internalization assays,
as described below.
Cathepsin activities were determined from 293T or L929 cell lysates
following transfection or incubation with cystatin F-enriched media, as
described below. Ten micrograms of postnuclear cell lysates was assayed
using either 50 mM H-Gly-Phe-AMC (cathepsin C) or 40 mM Z-Phe-Arg-
AMC (cathepsin L) in assay buffer containing 150 mM NaCl, 2 mM ethyl-
enediaminetetraacetic acid, 5 mM DTT and 100 mM citrate, pH 5.5. All
fluorometric assays were performed on a FLUOstar Optima Fluorimeter
(BMG) reading excitation at 360 nm and emission at 460 nm. Cathepsin
activity in 293T cells (cathepsin C) and L929 cells (cathepsin L) are
expressed as the rate of AMC release over time.
Size exclusion chromatography
Stokes’ radius determination of wild-type dimeric cystatin F, C26,63S
cystatin F and standard proteins were performed by size exclusion
chromatography using an Amersham HiLoad 26/60 Superdex 75 column
(Amersham Pharmacia). The column was pre-equilibrated in 50 mM phos-
phate buffer and 0.15 M NaCl, pH 7.2. Protein was loaded in 0.8 mL of
equilibration buffer in detergent-free conditions at a flow rate of 0.5 mL/min
at room temperature on the A ¨KTA fast protein liquid chromatography
system (Amersham Pharmacia) collecting 1 mL fractions. The elution
volumes of cystatin F and standard proteins (Ve) were converted into Kav
using the following equation; Kav ¼ (Ve   Vo)/(Vc   Vo), where Vo is the
void volume as determined by blue dextran and Vc is the calculated
geometric column volume (Vc ¼ r
2Q
L). The Stokes’ radius of cystatin F
was determined using a linear calibration plot of stokes’ radii versus ( log
Kav)
1/2 (48) obtained from standard proteins with known molecular weight
and stokes’ radii; ribonuclease A (13.7 kDa, 1.64 nm), carbonic anhydrase
(29k Da, 2.43 nm), ovalbumin (43 kDa, 3.05 nm) and conalbumin (75 kDa,
3.57 nm as calculated).
Radiolabeling
For [
35S] labeling, transfected 293T cells were preincubated in Met/Cys-free
media (Sigma), labeled for 45 min with 0.4 mCi/mL [
35S] Met/Cys (MP
Biomedical) and chased for 3 h in complete RPMI-medium containing
100 mg/mL methionine and 500 mg/mL cysteine. For [
32P] orthophosphate
labeling, transfected 293T cells were incubated for 30 min at 378Ci n
phosphate-free MEM containing 10% dialyzed FCS and for another 4 h in
the same medium supplemented with 0.5 mCi/mL [
32P] orthophosphate
(Perkin Elmer). Culture medium was removed and cells were washed
extensively and then lysed in buffer containing 1% Triton-X-100. Radio-
labeled cystatin F from culture medium and lysates were immunoprecipi-
tated using cystatin F antibodies (FL Ab) as described (16). Aliquots of
immunoprecipitated cystatin F were left untreated or digested with EndoH
as described (16). For
125I-labeling experiments, 20 mg of purified recom-
binant cystatin F was labeled with 0.5 mCi [
125I]-Na (Amersham) using the
IODO-GEN reagent (Pierce) following manufacturer’s instructions.
Internalization assay
To follow the internalization of cystatin F, L929 cells were cultured at
5   10
5/mL in 10-cm culture dishes or 2   10
5 on glass coverslips for 24 h
followed by the addition of normalized cystatin F supernatants taken from
293T cultures for an additional 24–48 h. The cells were then washed twice
in 100 mM glycine, pH 3.0, lysed and analyzed for cystatin F internalization
or cathepsin activity as described below. For studies using [
125I]-labeled
cystatin F, L929 cells were incubated with 500 mg/mL [
125I] cystatin F in the
presence or absence of 10 mM M6P at 48C. The cells were washed three
times with PBS to remove unbound protein and incubated at 378Cf o r
30 min to allow for internalization. Before lysis, cystatin F remaining on the
plasma membrane was removed by acid stripping (100 mM glycine, pH
3.0). Control cells were maintained at 08C throughout. Percent internaliza-
tion was determined by dividing the acid stable fraction following acid
washing at 30 min from the acid labile fraction at 0 min. Primary murine
CD8
þ T lymphocytes (CTL) and dendritic cells were isolated from the
spleen and bone marrow of C57Bl/6 mice as described (16,47). Primary
CD8
þ splenocytes from CD45.2
þ, cystatin F knockout mice or CD45.1
þ,
cystatin F-expressing mice were either cultured independently or at a 1:1
ratio for 48 h. Surface co-labeling of CD45.1 (fluorescein isothiocyanate)
and CD45.2 (APC) were detected by flow cytometry using directly
conjugated antibodies. Internalization of cystatin F was determined by
surface staining of either CD45.1 (APC) or CD45.2 (APC) followed by
intracellular staining for cystatin F (FL Ab) using the Fix & Perm cell
permeabilization kit (Caltag Laboratories).
Microscopy
Transfected 293T cells were grown on poly-L-lysine-coated coverslips for
48 h before staining. Cells were then fixed with 4% paraformaldehyde,
permeabilized with 0.2% Triton-X-100 and costained with rabbit anti-
cystatin F (FL Ab), and either mouse anti-CD63 or sheep anti-TGN46 in
the presence of 1% (w/v) BSA as described (16). For internalization assays,
L929 cells were grown on poly-L-lysine-coated coverslips for 18 h and
treated with cystatin F-containing conditioned media or control media as
described above. Primary antibodies were detected using Alexa-488 or
Alexa-594-conjugated anti-rabbit (Invitrogen), TR-conjugated anti-sheep
(pseudo-colored green) (Jackson Laboratory) and Alexa-488 anti-mouse
(Invitrogen) secondary antibodies. Stained cells were mounted on glass
slides and imaged on a LSM 510 META confocal microscope using a 100 
PlanFluar/NA 1.45 objective and LSM 510 software (Carl Zeiss Inc.) followed
by processing with Photoshop (Adobe).
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Figure S1: Cystatin F inhibitory activity depends on proper sub-
cellular localization. 293T cells were left alone or transfected with either
wild-type cystatin F or various glycosylation mutants. Cathepsin C activity
was determined using 10 mg of total protein from cell lysates. Data
represent the mean rate of cathpesin C activity from two independent
experiments.
Figure S2: Internalization of cystatin F is not inhibited in the presence
of free mannose or fucose. Equal concentrations of secreted wild-type
cystatin F produced by 293T cells were cultured with L929 cells for 48 h in
the absence (untreated) or presence of 10 mM of the free sugars indicated.
L929 cell lysates were separated by SDS–PAGE under nonreducing
conditions and blots stained for internalized cystatin F (Cyst. F)
Figure S3: Amino acid sequence alignment of cystatin F N-terminal
glycosylation motifs. Partial cystatin F sequence alignments were
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Glycosylation-Mediated Trafficking of Cystatin Fperformed using Geneious Basic (Biomatters Ltd) as described. Amino
acids 50–72 and 105–130 (human numbering) are displayed. Nonconsensus
N-linked glycosylation motifs (NXC) are shown in red, while consensus
sequences (NXS/T) are shown in blue. The sequence for Danio rerio was
found to be incomplete.
Figure S4: Internalization and activation of exogenously added cys-
tatin F in cystatin F-deficient splenocytes. A) Knockout splenocytes
were treated either with a medium control (white fill) or with 5 mM of
recombinant cystatin F (gray fill) for 48 h followed by intracellular cystatin F
staining by FACS analysis, (B) intracellular cystatin F staining by confocal
microscopy (green punctate stain) or (C) cathepsin C activity in postnuclear
cell lysates. Data are from protein equivalents and are the mean rate from
two independent experiments. Bars, 10 mm.
Please note: Wiley-Blackwell are not responsible for the content or
functionality of any supporting materials supplied by the authors. Any
queries (other than missing material) should be directed to the correspond-
ing author for the article.
References
1. Abrahamson M, Alvarez-Fernandez M, Nathanson CM. Cystatins.
Biochem Soc Symp 2003;70:179–199.
2. Kopitar-Jerala N. The role of cystatins in cells of the immune system.
FEBS Lett 2006;580:6295–6301.
3. Zeeuwen PL, van Vlijmen-Willems IM, Hendriks W, Merkx GF,
Schalkwijk J. A null mutation in the cystatin M/E gene of ichq mice
causes juvenile lethality and defects in epidermal cornification. Hum
Mol Genet 2002;11:2867–2875.
4. Bode W, Engh R, Musil D, Thiele U, Huber R, Karshikov A, Brzin J, Kos J,
TurkV.The2.0AX-raycrystalstructureofchickeneggwhitecystatinand
its possible mode of interaction with cysteine proteinases. EMBO
J 1988;7:2593–2599.
5. Stubbs MT, Laber B, Bode W, Huber R, Jerala R, Lenarcic B, Turk V.
The refined 2.4 A X-ray crystal structure of recombinant human stefin B
in complex with the cysteine proteinase papain: a novel type of
proteinase inhibitor interaction. EMBO J 1990;9:1939–1947.
6. Jenko S, Dolenc I, Guncar G, Dobersek A, Podobnik M, Turk D. Crystal
structure of Stefin A in complex with cathepsin H: N-terminal residues
of inhibitors can adapt to the active sites of endo- and exopeptidases.
J Mol Biol 2003;326:875–885.
7. Alvarez-Fernandez M, Barrett AJ, Gerhartz B, Dando PM, Ni J,
Abrahamson M. Inhibition of mammalian legumain by some cystatins
is due to a novel second reactive site. J Biol Chem 1999;272:
19195–19203.
8. Halfon S, Ford J, Foster J, Dowling L, Lucian L, Sterling M, Xu Y,
Weiss M, Ikeda M, Liggett D, Helms A, Caux C, Lebecque S, Hannum C,
Menon S et al. Leukocystatin, a new Class II cystatin expressed
selectively by hematopoietic cells. J Biol Chem 1998;273:
16400–16408.
9. Ni J, Fernandez A, Danielsson L, Chillakuru RA, Zhang J, Grub A, Su J,
Gentz R, Abrahamson M. Cystatin F is a glycosylated human low
molecular weight cystein proteinase inhibitor. J Biol Chem 1998;273:
24797–24804.
10. Cappello F, Gatti E, Camossetto V, David A, Lelouard H, Pierre P.
Cystatin F is secreted, but artificial modification of its C-terminus can
induce its endocytic targeting. Exp Cell Res 2004;297:607–618.
11. Langerholc T, Zavasnik-Bergant V, Turk B, Turk V, Abrahamson M, Kos J.
Inhibitory properties of cystatin F and its localization in U937 promon-
ocyte cells. The FEBS J 2005;272:1535–1545.
12. Schuettelkopf AW, Hamilton G, Watts C, van Aalten DM. Structural
basis of reduction-dependent activation of human cystatin F. J Biol
Chem 2006;281:16570–16575.
13. Nathanson CM, Wasselius J, Wallin H, Abrahamson M. Regulated
expression and intracellular localization of cystatin F in human U937
cells. Eur J Biochem 2002;269:5502–5511.
14. Taupin P, Ray J, Fischer WH, Suhr ST, Hakansson K, Grubb A, Gage FH.
FGF-2-responsive neural stem cell proliferation requires CCg, a novel
autocrine/paracrine cofactor. Neuron 2000;28:385–397.
15. Dahl A, Eriksson PS, Davidsson P, Persson AI, Ekman R, Westman-
Brinkmalm A. Demonstration of multiple novel glycoforms of the stem
cell survival factor CCg. J Neurosci Res 2004;77:9–14.
16. Hamilton G, Colbert JD, Schuettelkopf AW, Watts C. Cystatin F is
a cathepsin C-directed protease inhibitor regulated by proteolysis.
EMBO J 2008;27:499–508.
17. Pham CT, Ley TJ. Dipeptidyl peptidase I is required for the processing
and activation of granzymes A and B in vivo. Proc Natl Acad Sci U S A
1999;96:8627–8632.
18. Adkison AM, Raptis SZ, Kelley DG, Pham CT. Dipeptidyl peptidase I
activates neutrophil-derived serine proteases and regulates the devel-
opment ofacuteexperimental arthritis.J ClinInvest 2002;109:363–371.
19. Wolters PJ, Pham CT, Muilenburg DJ, Ley TJ, Caughey GH. Dipeptidyl
peptidase I is essential for activation of mast cell chymases, but not
tryptases, in mice. J Biol Chem 2001;276:18551–18556.
20. Sato C, Kim JH, Abe Y, Saito K, Yokoyama S, Kohda D. Characterization
of the N-oligosaccharides attached to the atypical Asn-X-Cys sequence
of recombinant human epidermal growth factor receptor. J Biochem
2000;127:65–72.
21. Vance BA, Wu W, Ribaudo RK, Segal DM, Kearse KP. Multiple dimeric
forms of human CD69 result from differential addition of N-glycans to
typical (Asn-X-Ser/Thr) and atypical (Asn-X-cys) glycosylation motifs.
J Biol Chem 1997;272:23117–23122.
22. Ghosh P, Dahms NM, Kornfeld S. Mannose 6-phosphate receptors:
new twists in the tale. Nature Rev Mol Cell Biol 2003;4:202–212.
23. Warfel AH, Zucker-Franklin D, Frangione B, Ghiso J. Constitutive
secretion of cystatin C (gamma-trace) by monocytes and macrophages
and its downregulationafter stimulation.J Ex Med 1987;166:1912–1917.
24. Isemura S, Saitoh E, Sanada K, Minakata K. Identification of full-sized
forms of salivary (S-type) cystatins (cystatin SN, cystatin SA, cystatin S,
and two phosphorylated forms of cystatin S) in human whole saliva and
determination of phosphorylation sites of cystatin S. J Biochem 1991;
110:648–654.
25. Balbin M, Hall A, Grubb A, Mason RW, Lopez-Otin C, Abrahamson M.
Structural and functional characterization of two allelic variants of
human cystatin D sharing a characteristic inhibition spectrum against
mammalian cysteine proteinases. J Biol Chem 1994;269:23156–23162.
26. Reddy VY, Zhang QY, Weiss SJ. Pericellular mobilization of the tissue-
destructive cysteine proteinases, cathepsins B, L, and S, by human
monocyte-derived macrophages. Proc Natl Acad Sci U S A 1995;92:
3849–3853.
27. Linebaugh BE, Sameni M, Day NA, Sloane BF, Keppler D. Exocytosis of
active cathepsin B enzyme activity at pH 7.0, inhibition and molecular
mass. Eur J Bicoem 1999;264:100–109.
28. Shi GP, Munger JS, Meara JP, Rich DH, Chapman HA. Molecular
cloning and expression of human alveolar macrophage cathepsin S, an
elastinolytic cysteine protease. J Biol Chem 1992;267:7258–7262.
29. Zeeuwen PL, Ishida-Yamamoto A, van Vlijmen-Willems IM, Cheng T,
Bergers M, Iizuka H, Schalkwijk J. Colocalization of cystatin M/E and
cathepsin V in lamellar granules and corneodesmosomes suggests a func-
tional role in epidermal differentiation. J Invest Derm 2007;127:120–128.
30. Journet A, Chapel A, Kieffer S, Louwagie M, Luche S, Garin J. Towards
a human repertoire of monocytic lysosomal proteins. Electrophoresis
2000;21:3411–3419.
436 Traffic 2009; 10: 425–437
Colbert et al.31. Dittmer F, Ulbrich EJ, Hafner A, Schmahl W, Meister T, Pohlmann R,
von Figura K. Alternative mechanisms for trafficking of lysosomal
enzymes in mannose 6-phosphate receptor-deficient mice are cell
type-specific. J Cell Sci 1999;112:1591–1597.
32. Nielsen MS, Madsen P, Christensen EI, Nykjaer A, Gliemann J, Kasper
D, Pohlmann R, Petersen CM. The sortilin cytoplasmic tail conveys
Golgi-endosome transport and binds the VHS domain of the GGA2
sorting protein. EMBO J 2001;20:2180–2190.
33. Grinnell BW, Walls JD, Gerlitz B. Glycosylation of human protein C
affects its secretion, processing, functional activities, and activation by
thrombin. J Biol Chem 1991;266:9778–9785.
34. Sando GN, Neufeld EF. Recognition and receptor-mediated uptake of
a lysosomal enzyme, alpha-l-iduronidase, by cultured human fibro-
blasts. Cell 1977;12:619–627.
35. York SJ, Arneson LS, Gregory WT, Dahms NM, Kornfeld S. The rate of
internalization of the mannose 6-phosphate/insulin-like growth factor II
receptor is enhanced by multivalent ligand binding. J Biol Chem 1999;
274:1164–1171.
36. Nielsen R, Courtoy PJ, Jacobsen C, Dom G, Lima WR, Jadot M,
Willnow TE, Devuyst O, Christensen EI. Endocytosis provides a major
alternative pathway for lysosomal biogenesis in kidney proximal tubular
cells. Proc Natl Acad Sci U S A 2007;104:5407–5412.
37. Kaseda R, Iino N, Hosojima M, Takeda T, Hosaka K, Kobayashi A,
Yamamoto K, Suzuki A, Kasai A, Suzuki Y, Gejyo F, Saito A. Megalin-
mediated endocytosis of cystatin C in proximal tubule cells. Biochem
Biophys Res Commun 2007;357:1130–1134.
38. Ullrich K, von Figura K. Endocytosis of beta-N-acetylglucosaminidase
from sections of mucolipidosis-II and-IIIfibroblastsbynon-parenchymal
rat liver cells. Biochem J 1979;182:245–247.
39. Ullrich K, Basner R, Gieselmann V, Von Figura K. Recognition of human
urine alpha-N-acetylglucosaminidase by rat hepatocytes. Involvement
of receptors specific for galactose, mannose 6-phosphate and man-
nose. Biochem J 1979;180:413–419.
40. Stahl P, Gordon S. Expression of a mannosyl-fucosyl receptor for
endocytosis on cultured primary macrophages and their hybrids. J Cell
Biol 1982;93:49–56.
41. Toyama-Sorimachi N, Kitamura F, Habuchi H, Tobita Y, Kimata K,
Miyasaka M. Widespread expression of chondroitin sulfate-type ser-
glycins with CD44 binding ability in hematopoietic cells. J Biol Chem
1997;272:26714–26719.
42. Harris EN, Weigel JA, Weigel PH. The human hyaluronan receptor for
endocytosis (HARE/Stabilin-2) is a systemic clearance receptor for
heparin. J Biol Chem 2008;283:17341–17350.
43. Grubb A, Lofberg H. Human gamma-trace, a basic microprotein: amino
acid sequence and presence in the adenohypophysis. Proc Natl Acad
Sci U S A 1982;79:3024–3027.
44. Ekstrom U, Wallin H, Lorenzo J, Holmqvist B, Abrahamson M,
Aviles FX. Internalization of cystatin C in human cell lines. FEBS J
2008;275:4571–4582.
45. Honey K, Benlagha K, Beers C, Forbush K, Teyton L, Kleijmeer MJ,
Rudensky AY, Bendelac A. Thymocyte expression of cathepsin L
is essential for NKT cell development. Nature Immunol 2002;3:
1069–1074.
46. Kasper D, Dittmer F, von Figura K, Pohlmann R. Neither type
of mannose 6-phosphate receptor is sufficient for targeting of lyso-
somal enzymes along intracellular routes. J Cell Biol 1996;134:
615–623.
47. West MA, Wallin RP, Matthews SP, Svensson HG, Zaru R, Ljunggren
HG, Prescott AR, Watts C. Enhanced dendritic cell antigen capture
via toll-like receptor-induced actin remodeling. Science 2004;305:
1153–1157.
48. Siegel LM, Monty KJ. Determination of molecular weights and
frictional ratios of proteins in impure systems by use of gel filtration
and density gradient centrifugation. Application to crude preparations
of sulfite and hydroxylamine reductases. Biochim Biophys Acta 1966;
112:346–362.
Traffic 2009; 10: 425–437 437
Glycosylation-Mediated Trafficking of Cystatin F